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Opinion statement
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the elderly, affecting
1 in 20 adults over the age of 70 years. Stroke is a major yet highly preventable com-
plication of AF, and the strokes related to AF often are disabling and fatal. Warfarin is
the treatment ofchoiceinhigh-risk patientswithAF,andits superiorefficacyoveraspirin
for preventing stroke in these patients is widely recognized. However, several eligible
patients with AF are not being treated with warfarin or are being treated inadequately,
largely because of concerns regarding the attendant strict monitoring, drug interactions,
and risk of major bleeding. As such, alternative antithrombotic therapies that can rival or
exceed the efficacy of warfarin, yet compare favorably with its administration and side
effect profile, are being sought. One such strategy, the use of a combination antiplatelet
regimen, for stroke prevention in high-risk patients with nonvalvular AF was investigated
recently in two clinical trials. This article reviews the role of combination antiplatelet
regimens in stroke prevention for patients with AF. Other therapies discussed include oral
anticoagulation,singleantiplatelettherapies,oralanticoagulationplusantiplatelettreat-




rapid contraction of the ventricles [1]. AFmay limit itself,
recur (paroxysmal), or be persistent (lasting more than
7 days), and its overall prevalence increases with age,
from0.7%inpersonsaged55to59yearsto18%inthose
85 years and older [2]. The major complication of AF is
systemic embolism (accounting for ∼50% of all cardio-
genicemboli),mostlyto the cerebral vascular bed, the
latter of which manifests as strokes. After adjustment
for other vascular risk factors, AF alone is associated
with a three-to fourfold increased risk of stroke, and
more than 75,000 cases of AF-related stroke are
believedtooccureachyearintheUnitedStates[2].These
strokes generally are larger, more disabling, and more
likely to be fatal than strokes of other causes.
Antithrombotic therapy is the cornerstone of stroke
prevention among AF patients, and the incidence ofischemic stroke among patients with AF not treated
with antithrombotic agents averages 4% to 5% per
year, and may be greater than 13% per year in high-
risk patients [3]. Oral anticoagulation, which generally
involves the use of warfarin, currently is the treatment
of choice for mitigating stroke risk in AF patients, but
its use is limited by a narrow therapeutic index that
demands strict monitoring, several drug and dietary
interactions, a lack of firm caregiver commitment to
ensure compliance with treatment and follow-up visits,
and the risk of major bleeding, including hemorrhagic
stroke [1]. Practitioners also have concerns about physi-
calimmobilityfromage-relatedhealthproblemsleading
to falls and hemorrhagic complications, and whether
participants in clinical trials, who generally are followed
up more closely to ensure adherence to the study proto-
col, are representative of patients seen in “real-world”
practice, who may not necessarily be compliant with
management protocols.
All the aforementioned factors have led to subopti-
mal warfarin use in clinical practice, with as many as
50%ofeligibleAFpatientsnotreceivingit,oruptothree
quartersnotbeingtreatedadequately.Asaresult,various
alternative antithrombotic therapies have, and continue
to be, actively investigated for stroke prevention in
patientswithAF.Onesuchregimeniscombinationanti-
platelet therapy. This review article discusses up-to-date
evidence-based antithrombotic treatment for stroke pre-
vention in AF patients, with a major emphasis on the
role of combination antiplatelet therapy.
Antithrombotic treatment
& Stroke in patients with AF is caused mainly by cardiogenic embolism.
Over the years, various clinical trials of antiplatelet and anticoagulant
medications to prevent stroke in AF have been conducted with the
goal of interrupting the presumed cardioembolic mechanism of
stroke in AF. In this section, the results of investigations of pertinent
antithrombotic regimens are discussed.
Single antiplatelet therapy (aspirin)
& Aspirin prevents platelet activation by inhibiting the enzyme
cyclooxygenase, thereby blocking thromboxane generation. A
pooled analysis of individual patient-level data from three trials
(Copenhagen Atrial Fibrillation, Aspirin and Anticoagulant
Therapy Study [AFASAK] 1; Stroke Prevention in Atrial Fibrillation
[SPAF] I; and European Atrial Fibrillation Trial [EAFT]) resulted in
an estimated relative risk (RR) reduction of 21% for aspirin
compared with placebo (95% CI, 0%–38%) [4]. The confidence
intervals for the pooled result indicate that the risk reduction
across trials was barely significant. Other meta-analyses of aspirin
versus control in AF patients have been conducted at the study
level, not the patient level, and suggest a 22% (95% CI, 2%–38%)
reduction in the risk of stroke in favor of aspirin [5].
Oral anticoagulation
& Pooled results from primary prevention trials of warfarin versus
control have shown the superior efficacy of warfarin, which was
consistent across studies, with an overall RR reduction of 68% (95%
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from 4.5% in the control patients to 1.4% in patients assigned to
adjusted-dose warfarin [6]. Overall, warfarin use has been shown
to be relatively safe, with an annual rate of major bleeding of
1.3% on warfarin compared with 1% for patients on placebo or
aspirin. The optimal intensity of oral anticoagulation for stroke
prevention in patients with AF appears to be 2.0 to 3.0. Data from
a large case-control study [7] and clinical trials [8, 9] indicate that
the efficacy of oral anticoagulation drops significantly below an
international normalized ratio (INR) of 2.0.
& Studies comparing oral anticoagulation directly with aspirin suggest
the risk reduction associated with oral anticoagulation therapy is
much greater than that provided by aspirin. A meta-analysis of these
studies reported a 36% (95% CI, 14%–52%) relative reduction in the
risk of all stroke with adjusted-dose oral anticoagulation compared
with aspirin and a 46% (95% CI, 27%–60%) reduction in the risk of
ischemic stroke [5]. A patient-level meta-analysis found an RR
reduction of 46% (95% CI, 29%–57%) for all stroke and 52%
(95% CI, 37%–63%) for ischemic stroke with anticoagulation versus
aspirin therapy [4]. Major hemorrhage was increased 1.7-fold (95%
CI for hazard ratio [HR], 1.21–2.41) (Table 1).
Oral anticoagulation plus antiplatelet therapy
& Because patients with AF often have coexisting atherosclerotic
vascular disease, it is thought that both warfarin and aspirin may
be necessary to simultaneously prevent thrombus formation in the
left atrium and arteries [1]. Combining low-dose oral anticoagu-
lation with aspirin appears to add relatively little protection
against stroke compared with aspirin alone in patients with AF,
whereas the combination of aspirin and oral anticoagulation at
higher intensities significantly boosted the risk of intracranial
hemorrhage, especially in elderly patients [10]. However, in the
National Study for Prevention of Embolism in Atrial Fibrillation
(NASPEAF), patients were stratified into a higher-risk group
Table 1. Main implications of ACTIVE-A versus prior warfarin data (from meta-analyses)
Effect Relative risk reduction, %
Warfarin vs aspirin
(meta-analyses) [20]
Clopidogrel plus aspirin vs
aspirin (ACTIVE-A) [14.••]
Reduction in stroke −38 −28
Increase in intracranial hemorrhages +128 +87
Increase in extracranial hemorrhages +70 +51
ACTIVE-A—Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events
(Adapted from Stuart J. Connolly, MD; with permission)
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lower-risk group (AF and age 960 years, hypertension, or heart
failure) [11]. The higher-risk patients were randomly assigned to
treatment with anticoagulation (INR 1.4–2.4) combined with the
platelet cyclooxygenase inhibitor triflusal (600 mg/d, approxi-
mately equivalent to 300 mg of aspirin) or anticoagulation (INR
2.0–3.0) alone. The lower-risk patients were randomly assigned to
receive triflusal alone, anticoagulation (INR 2.0–3.0) alone, or
triflusal plus anticoagulation to an INR of 1.25 to 2.0. The group
receiving combination therapy had a significantly lower risk of
primary outcome events (thromboembolism plus cardiovascular
death) than the group treated with anticoagulation alone in both
risk groups. Rates of severe bleeding, including intracerebral hemor-
rhage, were lower in the combination therapy arm than in the antico-
agulation-only arm, but this difference was not statistically significant.
However, it should be noted that the differences in primary outcome
resulted largely from outcomes that probably were not a result of
thromboembolism and that the achieved INR levelswere similarinthe
anticoagulation and combination therapy groups.
& Currently, there is no evidence that combining anticoagulation with
an antiplatelet agent reduces the risk of stroke or myocardial infarc-
tion compared with anticoagulant therapy alone in AF patients, but
there is clear evidence of increased bleeding risk [10]. Therefore, in
general, aspirin should not be added to anticoagulation therapy for
AF patients without compelling indications for antiplatelet therapy.
Combination antiplatelet therapy
& Presently there are few data regarding the efficacy of combining
antiplatelet agents for stroke prevention in AF patients [12]. Available
studies have examined the clinical impact of aspirin plus clopidogrel
in AF patients. Clopidogrel is an adenosine diphosphate (ADP)
receptor antagonist. Clopidogrel selectively and irreversibly inhibits
ADP-induced fibrinogen binding to its receptor on platelets, thereby
affecting ADP-dependent activation of the glycoprotein IIb/IIIa
complex, the major receptor for fibrinogen present on the platelet
surface. The value of combination antiplatelet therapy for stroke
prevention in patients with AF was assessed in two ACTIVE (Atrial
Fibrillation Clopidogrel Trial With Irbesartan for Prevention of
Vascular Events) trials, ACTIVE-W [13] and ACTIVE-A [14.••].
& ACTIVE-W evaluated the safety and efficacy of the combination of
clopidogrel and aspirin versus warfarin in AF patients with at least
one risk factor for stroke. This study was stopped prematurely by the
safety monitoring committee after 3371 patients were enrolled
because of the clear superiority of warfarin (INR 2.0–3.0) over the
antiplatelet combination (RR, 1.44; 95% CI, 1.18–1.76; P=0.0003).
Random assignment to clopidogrel (75 mg once daily) plus aspirin
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primary outcome of stroke, myocardial infarction, non–central
nervous system (CNS) systemic embolism, or death from vascular
causes after a median follow-up of 1.3 years compared with assign-
ment to warfarin (target INR 2.0–3.0; 5.6% vs 3.9%; RR, 1.44; 95%
CI, 1.18–1.76). There was no significant difference in major bleeding
between the two treatment groups (2.4% per year for those on
clopidogrel plus aspirin vs 2.2% per year for those on warfarin; RR,
1.10; 95% CI, 0.83–1.45). A subgroup analysis of the results of this
trial raised the hypothesis that most of the benefit of warfarin over
the combination of aspirin and clopidogrel was in patients who were
already taking and tolerating oral anticoagulant therapy (ie, had
survived the warfarin stress test), compared with patients who were
warfarin naïve and about to start warfarin. Patients who were already
taking warfarin at study entry and were randomly assigned to
continue oral anticoagulation therapy had a substantial reduction
in vascular events compared with those on the combination of
clopidogrel and aspirin (3.7% vs 5.5% per year; RR, 0.67; 95% CI,
0.55–0.84) and a significantly lower risk of major bleeding (2.0%
vs 2.6% per year; RR, 0.77; 95% CI, 0.56–1.06). By contrast, patients
who were not taking oral anticoagulants at study entry (ie, those who
were warfarin naïve) and were randomly assigned to start oral antico-
agulation had a similar rate of vascular events (4.7% vs 5.9% per year;
RR,0.79;95%CI,0.53–1.18)andahigherriskofmajorbleeding(2.9%
vs1.7%peryear;RR,1.69;95%CI,0.93–3.12)comparedwiththoseon
the combination of clopidogrel and aspirin.
& ACTIVE-A followed an approach similar to that of ACTIVE-W but
selected patients with AF for whom therapy with a vitamin K
antagonist (VKA) was considered unsuitable. ACTIVE-A randomly
assigned patients to receive clopidogrel plus aspirin or aspirin plus
placebo. The reasons patients were not considered suitable for VKA
therapy or enrollment in ACTIVE-W included the presence of a spe-
cific risk factor for bleeding (23%), a physician assessment that the
patient was not an appropriate candidate (50%), and a patient
preference not to receive a VKA (26%). After a median follow-up of
3.6 years, compared with aspirin alone, clopidogrel once daily plus
aspirin was associated with a reduction in the primary outcome of
stroke, myocardial infarction, non-CNS systemic embolism, or death
from vascular causes (6.8% vs 7.6% per year; RR, 0.89; 95% CI, 0.81–
0.98; P=0.01), mainly because of a reduction in the rate of stroke
(2.4% vs 3.3% per year; RR, 0.72; 95% CI, 0.62–0.83; PG0.001)
(Table 1, Table 2). The benefit of the combination in reducing major
vascular events, however, was balanced by an increased risk of major
hemorrhages (major vascular events decreased 0.8% per year, major
hemorrhages increased 0.7% per year; RR, 0.97; 95% CI, 0.89–1.06;
P=0.54). Major bleeding among patients assigned to receive clopi-
dogrel plus aspirin versus those on aspirin alone was 2.0% versus
254 Cerebrovascular Disease and Stroke1.3% per year (RR, 1.57; 95% CI, 1.29–1.92). Clopidogrel plus
aspirin reduced the risk of stroke by 28% but increased the risk of
major extracranial hemorrhage by 51% (affecting predominantly the
gastrointestinal tract) and major intracranial hemorrhage by 87%
(Table 1).
Direct thrombin inhibitors
& Ximelagatran, a direct thrombin inhibitor, was compared with dose-
adjusted warfarin in two major randomized controlled trials. In
pooled analyses of both trials [10], the rate of main events (combined
ischemic stroke, hemorrhagic stroke, and systemic embolic event) was
similar in the ximelagatran and warfarin groups (1.62% vs 1.65% per
year). Conflated rates of minor and major bleeding were lower with
ximelagatran (31.7% vs 38.7% per year; PG0.0001), but serum alanine
aminotransferase values rose transiently to more than three times the
normallevelin the subjectson ximelagatran (6.1%vs0.8%;PG0.0001).
Althoughtheseincreasesusuallyarereversible,theyledtheUSFoodand
Drug Administration (FDA) to decide against approving ximelagatran
for stroke prevention.
& Dabigatran etexilate is a prodrug given orally in a fixed dose and
quickly converted by cytochrome P-450–independent esterases to
dabigatran, a powerful reversible direct competitive inhibitor of
thrombin with a prompt onset of action, consistent anticoagulant
effect, and half-life of 12 to 17 h. RE-LY (Randomized Evaluation of
Long-Term Anticoagulant Therapy), a prospective, open-label, ran-
domized trial with blinded assessment of all outcomes, investigated
whether dabigatran is noninferior to warfarin. [15.••]. More than
18,000 patients with nonvalvular AF and at least one risk factor for
stroke were randomly assigned to receive fixed doses of dabigatran
(110 or 150 mg twice daily) or open-label, adjusted-dose warfarin
(INR 2.0–3.0). After 2 years, the rates of systemic embolism or stroke




Aspirin Clopidogrel plus aspirin
vs aspirin
Outcomes Definition Number Rate/year Number Rate/year Relative risk 95% CI P-value
Primary Composite 832 6.8 924 7.6 0.89 0.81–0.98 0.014
Secondary Stroke 296 2.4 408 3.3 0.72 0.62–0.83 G0.001
Myocardial infarction 90 0.7 115 0.9 0.78 0.59–1.03 0.08
Vascular death 600 4.7 599 4.7 1.0 0.89–1.12 0.97
Non-CNS embolism 54 0.4 56 0.4 0.96 0.66–1.40 0.84
ACTIVE-A—Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events; CNS—central nervous system
(Adapted from Stuart J. Connolly, MD; with permission)
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(1.53% per year) and those who received warfarin (1.69% per year;
HR, 0.91; 95% CI, 0.74–1.11; PG0.001) and lower among patients
who received dabigatran, 150 mg twice daily (1.11% per year; HR,
0.66; 95% CI, 0.53–0.82). Compared with warfarin (3.36% per
year), the yearly rate of major bleeding was lower among patients
who received 110 mg dabigatran (2.71% per year; RR, 0.80; 95% CI,
0.69–0.93) but similar among those assigned 150 mg dabigatran
(3.11% per year; RR, 0.93; 95% CI, 0.81–1.07). Compared with
warfarin taken once daily, dabigatran is given twice daily, but the
level of anticoagulation does not need to be monitored. Other drugs
may interact with dabigatran, and its effects may not be reversed
readily in patients with bleeding complications.
Factor Xa inhibitors
& Idraparinux is an analogue of the heparin pentasaccharide that binds
irreversibly to antithrombin and stimulates a change leading to
inactivation of activated factor X. It has a half-life of 80 to 130 h and
is given by subcutaneous injection once weekly. Compared with
warfarin, idraparinux has been associated with substantially higher
bleeding rates [16.•]. A clinical trial that randomly assigned 4576 AF
patients to receive subcutaneous idraparinux (2.5 mg/wk) or
adjusted-dose VKA therapy (target INR 2.0–3.0) had to be stopped
after a mean follow-up of 11 months because of excess major
bleeding among patients assigned to idraparinux versus VKA therapy
(19.7 vs 11.3 events per 100 patient-years; HR, 1.74; 95% CI, 1.47–
2.06). Older patients and those with renal insufficiency were at
greaterriskforsuchcomplications.Therewasnodifferenceintherateof
stroke and systemic embolism (0.9 vs 1.3 events per 100 patient-years;
HR, 0.71; 95% CI, 0.39–1.30; P=0.007 for noninferiority) or
death (3.2 vs 2.9 deaths per 100 patient-years; P=0.49) between
patients on idraparinux and those receiving VKA therapy. Several
oral and subcutaneous factor Xa inhibitors currently are under-
going clinical evaluation.
Current guidelines
& Guidelines from the American Heart Association/American Stroke
Association [3] and the American College of Chest Physicians [17.•]
have not yet been updated to reflect the results of the ACTIVE-A and
RE-LY trials but include the following:
– Initiate oral anticoagulation within 2 weeks of an ischemic stroke
or transient ischemic attack (TIA); however, for patients with
large infarcts, hemorrhagic transformation, or uncontrolled
hypertension, further delays may be appropriate.
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therapeutic anticoagulation, there are no data indicating that
either increasing the intensity of anticoagulation or adding an
antiplatelet agent provides additional protection against future
ischemic events. In addition, both these strategies are associated
with an increase in bleeding risk.
– Initiate warfarin for patients with AF and a moderate to high risk
of stroke, such as those with a) mitral stenosis or a prosthetic
heart valve, b) a history of prior ischemic stroke or systemic
embolism, or c) two or more thromboembolic risk factors.
– In patients with AF, including those with paroxysmal AF, with
only one major risk factor, initiate long-term antithrombotic
therapy eitherasanticoagulationwithanoralVKA,suchaswarfarin,
targeted at an INR of 2.5 (range, 2.0–3.0), or as aspirin, at a dose of
75to325mg/d.Forpatientsatintermediateriskforischemicstroke,
a VKA, rather than aspirin, is recommended.
– In patients with AF, including those with paroxysmal AF, aged
75 years or older with no major risk factors, initiate long-term
aspirin therapy at a dose of 75 to 325 mg/d because of their
low risk of ischemic stroke.
FDA-approved treatments
Pharmacologic treatment
& The current FDA-approved pharmacologic therapies for stroke pre-
vention in patients with AF include dose-adjusted warfarin (targeted
to INR 2.0–3.0) and antiplatelet agents, as discussed earlier [18, 19].
The only antiplatelet agents discussed in this section are aspirin and
clopidogrel, as these are the two antiplatelets shown to reduce the
rate of stroke in patients with AF.
Antiplatelet agents
Aspirin
Standard dosage 75 to 325 mg/d orally.
Contraindications Hypersensitivity to nonsteroidal anti-inflammatory drugs;children and
teenagers with chickenpox or flu symptoms (risk of Reye’ss y n d r o m e ) ;
syndrome of asthma, rhinitis, and nasal polyps.
Main drug interactions Ketorolac, citalopram, desvenlafaxine, dicumarol, duloxetine, eptifibatide,
escitalopram, fluoxetine, fluvoxamine, ginkgo, heparin, ketoprofen, metho-
trexate, nefazodone, paroxetine, sertraline, ticlopidine, varicella virus vaccine,
venlafaxine, warfarin.
Main side effects Gastrointestinal ulcers, bleeding, tinnitus, bronchospasm, angioedema,
Reye’s syndrome.
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drug should not be used in children because of the risk of Reye’s syndrome. It
shouldneverbeusedinchildrenandteenagerswithchickenpoxorflusymptoms.
Cost/cost-effectiveness 325-mg tablets (1 bottle, 100 each): $11.99; 81-mg enteric coated tablets
(1000 each): $46.00: 975-mg enteric coated tablets (90 each): $11.25;
325-mg enteric coated tablets (14 bottles, 100 each): $46.06.
Clopidogrel
Standard dosage 75 mg/d orally.
Contraindications Active bleeding (eg, peptic ulcer or intracranial hemorrhage; hypersensitivity
to clopidogrel.
Main drug interactions Abciximab, recombinant alteplase, argatroban, cilostazol, cimetidine,
citalopram, dalteparin, desvenlafaxine, dicumarol, duloxetine, enoxaparin,
eptifibatide, escitalopram, felbamate, fluconazole, fluoxetine, fluvox-
amine, fondaparinux, heparin, ketoconazole, lansoprazole, nefazodone,
omeprazole, pantoprazole, paroxetine, recombinant reteplase, sertraline,
streptokinase, ticlopidine, urokinase, venlafaxine, voriconazole, warfarin.
Main side effects Chest pain, hypertension, pruritus, purpuric disorder, rash, hypercholesterol-
emia, abdominal pain, constipation, gastritis, indigestion, epistaxis, purpura,
arthralgia, backache, headache.
Special points There have been reports of thrombotic thrombocytopenic purpura after
exposure to clopidogrel.
Cost/cost-effectiveness 75-mg tablets (30 each): $155.99.
Oral anticoagulation
Warfarin
Standard dosage Initially, 2 to 5 mg/d orally; adjust dosage based on the INR.
Contraindications Threatened abortion; eclampsia; preeclampsia; alcoholism; major regional or
lumbar anesthesia; cerebral aneurysms; dissecting aortic aneurysms; bacterial
endocarditis; bleeding tendencies of the gastrointestinal, genitourinary,
or respiratory tract; blood dyscrasias; cerebrovascular hemorrhage; gas-
trointestinal, genitourinary, or respiratory tract ulcerations or overt
bleeding; hypersensitivity to warfarin; inadequate laboratory facilities; malig-
nant hypertension; pericarditis and pericardial effusion; pregnancy; lack of pa-
tient cooperation; spinal puncture and other procedures with potential for
uncontrollable bleeding; recentorpotentialsurgery ofthe CNSoreye;recent or
potential traumatic surgery resulting in a large open surface.
Main drug interactions Abciximab, recombinant alteplase, amiodarone, aspirin, carboplatin, cele-
coxib, chamomile, cilostazol, citalopram, clopidogrel, cyclophosphamide,
dalteparin, desvenlafaxine, dicumarol, doxorubicin, duloxetine, enoxaparin,
eptifibatide, escitalopram, etoposide, fenofibrate, fish oil, fluconazole,
fluorouracil, fluoxetine, fluvoxamine, fondaparinux, garlic, ginkgo, heparin,
influenza virus vaccine, ketoprofen, levofloxacin, marijuana, methotrexate,
metronidazole, moxifloxacin, naproxen, papaya, paroxetine, pomegranate,
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John’s wort, streptokinase, sulfamethoxazole, testosterone, urokinase, ven-
lafaxine, vincristine, voriconazole.
Main side effects Cholesterol embolus syndrome, tissue necrosis, hemorrhage, hypersensitivity
reaction (infrequent), intraocular hemorrhage.
Special points Warfarinmaycausemajororfatalbleeding.Riskfactorsforbleedingincludeahigh
intensity of anticoagulation (INR 94.0), age≥65 years, highly variable INRs, a
history of gastrointestinal bleeding, hypertension, cerebrovascular disease, serious
heartdisease,anemia,malignancy,trauma,renalinsufficiency,concomitantdrugs,
and a long duration of warfarin therapy. Regular monitoring of INR is necessary.
There are multiple significant drug–drug interactions. Patients should avoid alco-
hol, cranberry juice, and eating large amounts of food high in vitamin K.
Cost/cost-effectiveness 1-mg tablets (30 each): $13.99; 2-mg tablets (30 each): $14.88; 2.5-mg
tablets(30each):$14.99;3-mgtablets(30each):$15.99;4-mgtablets(30each):
$14.99; 5-mg tablets (30 each): $13.99; 7.5-mgtablets (30 each):$23.21; 10-mg
tablets (30 each): $24.24.
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